138 related articles for article (PubMed ID: 36786360)
1. Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid.
Solimani F; Mesas-Fernández A; Bodner E; Carevic-Neri M; Hasheminasab M; Jakovljevicova T; Philipp A; Nast A; Worm M; Hilke FJ; Meier K; Ghoreschi K
J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):e695-e697. PubMed ID: 36786360
[No Abstract] [Full Text] [Related]
2. The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?
Damiani G; Pacifico A; Pelloni F; Iorizzo M
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e645-e647. PubMed ID: 34169578
[No Abstract] [Full Text] [Related]
3. Incident bullous pemphigoid in a psoriatic patient following mRNA-1273 SARS-CoV-2 vaccination.
Hung WK; Chi CC
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e407-e409. PubMed ID: 35073431
[No Abstract] [Full Text] [Related]
4. COVID-19 and autoimmune bullous diseases: Lessons learned.
Kasperkiewicz M; Woodley DT
Autoimmun Rev; 2023 Apr; 22(4):103286. PubMed ID: 36738951
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review.
Calabria E; Canfora F; Mascolo M; Varricchio S; Mignogna MD; Adamo D
Pathol Res Pract; 2022 Apr; 232():153834. PubMed ID: 35278817
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune skin disorders and SARS-CoV-2 vaccination - a meta-analysis.
Hinterseher J; Hertl M; Didona D
J Dtsch Dermatol Ges; 2023 Aug; 21(8):853-861. PubMed ID: 37218538
[TBL] [Abstract][Full Text] [Related]
7. Reply to 'The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?' by Damiani G et al.
Avallone G; Giordano S; Astrua C; Merli M; Senetta R; Conforti C; Ribero S; Marzano AV; Quaglino P
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e433-e435. PubMed ID: 35067994
[No Abstract] [Full Text] [Related]
8. Urticaria 12 Days After COVID-19 mRNA Booster Vaccination.
Wolfson AR; Freeman EE; Blumenthal KG
JAMA; 2022 May; 327(17):1702-1703. PubMed ID: 35420647
[No Abstract] [Full Text] [Related]
9. In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine.
Muthukumar A; Narasimhan M; Li QZ; Mahimainathan L; Hitto I; Fuda F; Batra K; Jiang X; Zhu C; Schoggins J; Cutrell JB; Croft CL; Khera A; Drazner MH; Grodin JL; Greenberg BM; Mammen PPA; Morrison SJ; de Lemos JA
Circulation; 2021 Aug; 144(6):487-498. PubMed ID: 34133883
[TBL] [Abstract][Full Text] [Related]
10. Pemphigus vulgaris after SARS-CoV-2 vaccination: A case with new-onset and two cases with severe aggravation.
Akoglu G
Dermatol Ther; 2022 May; 35(5):e15396. PubMed ID: 35187768
[TBL] [Abstract][Full Text] [Related]
11. Bullous pemphigoid after SARS-CoV-2 vaccination: spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies.
Gambichler T; Hamdani N; Budde H; Sieme M; Skrygan M; Scholl L; Dickel H; Behle B; Ganjuur N; Scheel C; Abu Rached N; Ocker L; Stranzenbach R; Doerler M; Pfeiffer L; Becker JC
Br J Dermatol; 2022 Apr; 186(4):728-731. PubMed ID: 34773638
[No Abstract] [Full Text] [Related]
12. A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine.
Young J; Mercieca L; Ceci M; Pisani D; Betts A; Boffa MJ
J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):e13-e16. PubMed ID: 34547137
[No Abstract] [Full Text] [Related]
13. Audio Interview: New Evidence on SARS-CoV-2 Vaccine Boosters.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Sep; 385(12):e48. PubMed ID: 34525292
[No Abstract] [Full Text] [Related]
14. Chronic oral diseases secondary to COVID-19 infection or vaccination: clinical cases and a narrative review.
Fitzpatrick S; Cha S; Katz J; Migliorati C
Quintessence Int; 2024 May; 55(5):400-411. PubMed ID: 38415994
[TBL] [Abstract][Full Text] [Related]
15. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Shaw RH; Stuart A; Greenland M; Liu X; Nguyen Van-Tam JS; Snape MD;
Lancet; 2021 May; 397(10289):2043-2046. PubMed ID: 33991480
[No Abstract] [Full Text] [Related]
16. COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation.
Kasperkiewicz M; Strong R; Mead K; Yale M; Zillikens D; Woodley DT; Recke A
Br J Dermatol; 2022 Apr; 186(4):737-739. PubMed ID: 34842282
[No Abstract] [Full Text] [Related]
17. A case of acquired hemophilia A and bullous pemphigoid following SARS-CoV-2 mRNA vaccination.
Fu PA; Chen CW; Hsu YT; Wei KC; Lin PC; Chen TY
J Formos Med Assoc; 2022 Sep; 121(9):1872-1876. PubMed ID: 35321820
[TBL] [Abstract][Full Text] [Related]
18. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune bullous disorder flares following severe acute respiratory syndrome coronavirus 2 vaccination: a case series.
Rasner CJ; Schultz B; Bohjanen K; Pearson DR
J Med Case Rep; 2023 Sep; 17(1):408. PubMed ID: 37749657
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 vaccine-triggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitors-associated bullous pemphigoid.
Nakahara Y; Yamane M; Sunada M; Aoyama Y
J Dermatol; 2023 Feb; 50(2):162-165. PubMed ID: 36578130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
